{
  "data_version": "seed-0.7 · marketcap-1 · 2026-08-30",
  "source": "https://finance.foundation",
  "license": {
    "finance_foundation_data": "CC BY 4.0 — attribution: Finance Foundation (https://finance.foundation)",
    "upstream_values": "Fields sourced from a provider carry their own source field and remain under that provider's terms — see https://finance.foundation/api/v1/sources"
  },
  "entity": "company",
  "data": {
    "id": "csl",
    "name": "CSL",
    "legal_name": "CSL Limited",
    "ticker": "CSL",
    "exchange": "asx",
    "country": "australia",
    "sector": "Healthcare",
    "industry": "Plasma therapies & vaccines",
    "market_cap_usd_bn": 59.4,
    "currency": "AUD",
    "website": "https://www.csl.com",
    "founded": 1916,
    "description": "Australian biotech and one of the world's largest makers of plasma-derived therapies (CSL Behring), also active in influenza vaccines (Seqirus) and iron-deficiency and nephrology treatments (Vifor).",
    "identifiers": {
      "lei": "529900ECSECK5ZDQTE14",
      "isin": "AU000000CSL8",
      "figi": "BBG001S7YNK1"
    },
    "market_cap_seed_usd_bn": 65,
    "market_cap_basis": "computed",
    "market_cap_as_of": "2026-08-28",
    "market_cap": {
      "usd_bn": 59.4,
      "method": "shares_outstanding x price",
      "shares_outstanding": 478911979,
      "shares_basis": "outstanding",
      "shares_as_of": "2026-08-27",
      "shares_source": "ASX Appendix 3G 'Notification regarding unquoted securities",
      "shares_source_url": "https://investors.csl.com/pdf/05edf437-8e41-4699-89a2-61d3d915656d/Platform/ListPage/Notification-regarding-unquoted-securities-CSL.pdf)",
      "price": 172.32,
      "price_currency": "AUD",
      "price_date": "2026-08-28",
      "price_symbol": "CSL.AX",
      "price_venue": "ASX",
      "fx": "ECB euro reference rates, 2026-08-28",
      "adr_ratio": 0.25,
      "caveat": "ADR ratio changed in 2026 - this is the main trap. Cslly was 2 ADSs : 1 ordinary share (1 ADR = 0.5 share) until an effective 2:1 ADR split on 2 March 2026; it is now 4 ADRs : 1 ordinary share, i.e. 1 ADR = 0.25 ordinary shares."
    }
  },
  "field_provenance": {
    "market_cap_usd_bn": "Computed, not copied: shares outstanding from the issuer's own filing x the closing price on its home listing. The inputs, their dates and the filing URL are in the `market_cap` object; null means we hold no share count we can source. `market_cap_seed_usd_bn` is the superseded hand-entered value, kept only so the two can be told apart.",
    "founded": "Company's own corporate history / registration record.",
    "sector": "Finance Foundation classification, not GICS or ICB (both licensed).",
    "identifiers": {
      "lei": "GLEIF (CC0) — free to redistribute",
      "isin": "Issuer's own primary listing document; ISO 6166 check digit validated. For a company carried via its US ADR this is the ADR ISIN — see us_listing_type",
      "figi": "OpenFIGI (open standard) — free to redistribute"
    }
  },
  "links": {
    "html": "https://finance.foundation/companies/csl",
    "graph": "https://finance.foundation/api/v1/graph/companies/csl",
    "sources": "https://finance.foundation/api/v1/sources"
  }
}